Imagine finding a new use for a tool you already own instead of buying a brand new one. This project does that with medicines, finding new diseases that existing, safe drugs can treat. It creates a shared system to move these 'recycled' drugs from the lab to the patient much faster.
Developing new drugs is prohibitively expensive and slow, while thousands of diseases remain untreated. There is a lack of a coordinated system to efficiently move existing, safe drugs into new therapeutic uses.
A permanent European research and innovation platform. This includes a harmonized value chain and template materials for joint calls, such as governance and controller agreements.
If you are a drug developer dealing with the high cost of starting new molecules from scratch — this project developed a value chain that allows you to use already approved drugs to treat new diseases at a fraction of the cost.
If you are a startup dealing with the gap between AI predictions and clinical reality — this project developed a platform integrating in silico tools with 26 sites across 11 countries to validate findings faster.
If you are a CRO dealing with complex regulatory hurdles for rare diseases — this project developed harmonized templates and guidelines for joint calls and governance to streamline the path to clinic.
Based on available project data, repurposing existing medicines can be done at a fraction of the cost of developing a completely new drug from scratch.
Yes, the platform already spans 26 sites across 11 different countries in Europe and the UK.
The platform integrates the legal and intellectual property aspects of the repurposing approach into a harmonized value chain.
The project involves medicines regulators and provides template materials for joint calls, including Memorandum of Understanding and Joint Controller Agreements.
The project runs from September 2022 to August 2027, with 4 preclinical and clinical phase demonstrators used for validation.
The consortium is well-balanced for commercial translation, featuring 28 partners with an 18% industry ratio (5 companies, including 5 SMEs). The heavy presence of 11 research entities and 8 universities ensures scientific rigor, while the coordination by EATRIS ERIC provides the necessary infrastructure to bridge the gap between lab discovery and market application.
Contact EATRIS ERIC in the Netherlands
Contact us to explore partnership opportunities with the REMEDi4ALL platform.
